TherapeuticsMD (TXMD) Misses Q1 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
TherapeuticsMD Announces First Quarter 2020 Financial Results
May 6, 2020 6:50 AM EDT- 1Q20 total net product revenue of $12.3 million exceeded Wall Street consensus -
- Significantly reducing operating expenses, while maintaining goal of achieving EBITDA breakeven in 2021 -
- In discussions with TPG Sixth Street Partners to defer the scheduled start of quarterly revenue covenants due to COVID-19 -
- First Orange Book listed patent for ANNOVERA® issued providing potential extended exclusivity to 2039 -
- Strengthened board of directors with diverse industry veterans -
- Conference call scheduled for... More
